Simon Fishman, M.D.
Specialist
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,386
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
VA license 0101225797
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Virginia Hospital Center Arlington, VA
- Inova Alexandria Hospital Alexandria, VA
- Inova Mount Vernon Hospital Alexandria, VA
- Sentara Northern Virginia Medical Center Woodbridge, VA
Medical groups
- Integrated Neurology Services (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,386
- Services billed
- 43,716
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 33,200 | 68 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,098 | 643 |
| Established patient office or other outpatient visit, 20-29 minutes | 568 | 400 |
| New patient office or other outpatient visit, 45-59 minutes | 292 | 292 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 272 | 242 |
| Established patient office or other outpatient visit, 40-54 minutes | 248 | 174 |
| New patient office or other outpatient visit, 60-74 minutes | 183 | 183 |
| Administration of chemotherapy into vein, each additional hour | 128 | 20 |
| Injection, zoledronic acid, 1 mg | 105 | 21 |
| Administration of chemotherapy into vein, 1 hour or less | 100 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Alexandria, VA | 40 |
| Baclofen Other prescribers in Alexandria, VA | 33 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Alexandria, VA | 28 |
| Botox (onabotulinumtoxina) | 25 |
| Mirtazapine Other prescribers in Alexandria, VA | 25 |
| Nortriptyline Hcl Other prescribers in Alexandria, VA | 20 |
| Primidone Other prescribers in Alexandria, VA | 18 |
| Duloxetine Hcl Other prescribers in Alexandria, VA | 16 |
| Dalfampridine Er (dalfampridine) | 16 |
| Trazodone Hcl Other prescribers in Alexandria, VA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 237 payments worth $20,766 in total to this clinician.
| Biogen, Inc. | $15,137 |
|---|---|
| AbbVie Inc. | $952 |
| EMD Serono, Inc. | $621 |
| Medtronic, Inc. | $568 |
| Axsome Therapeutics, Inc. | $493 |
| Celgene Corporation | $372 |
| Amgen Inc. | $332 |
| Pfizer Inc. | $274 |
| Compensation for services other than consulting (speaking, faculty) | $13,450 |
|---|---|
| Food and Beverage | $6,523 |
| Consulting Fee | $404 |
| Travel and Lodging | $389 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Biogen, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) TYSABRI · Neurology | $4,304 |
| Biogen, Inc. Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) TYSABRI · Neurology | $3,766 |
| Biogen, Inc. Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) TYSABRI · Neurology | $3,766 |
| Biogen, Inc. Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) TYSABRI · Neurology | $1,614 |
| Biogen, Inc. Aug 11, 2025 | Consulting Fee TYSABRI · Neurology | $269 |
| Biogen, Inc. Apr 10, 2025 | Travel and Lodging TYSABRI · Neurology · travel to Henrico, VA | $240 |
| Biogen, Inc. Apr 10, 2025 | Travel and Lodging TYSABRI · Neurology · travel to Henrico, VA | $149 |
| Biogen, Inc. Jan 2, 2025 | Consulting Fee | $135 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $45,662 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Novo Nordisk As - M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
AbbVie Inc. - Evaluation of Fenebrutinib in RMS patients II
Genentech, Inc. - M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
AbbVie Inc. - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
AbbVie Inc. · Completed · NCT05216263 - Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple scle…
EMD Serono, Inc. - A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.